Want to see INBX full AI Analyst Report?
Top Page
Inhibrx Biosciences Inc
(NASDAQ:INBX)
Select Model
Select Model
Rating:50Neutral
Price Target:
$89.00
▲(9.14% Upside)
Action:Reiterated
Date:07/17/26
The score is held back primarily by very weak financial performance (large losses, heavy cash burn, and negative equity). Technicals are also cautious with the stock trading below key moving averages and a negative MACD. These risks are partially offset by strongly positive corporate events—BLA acceptance and favorable clinical updates—along with improved access to capital via an expanded credit facility.
Positive Factors
Regulatory milestone - BLA acceptance
BLA acceptance is a durable de-risking step that moves ozekibart from trial-stage toward commercialization. If approved, it would be the company's first product and the first systemic therapy for this rare cancer, creating a unique market position and potential sustained revenue stream.
Negative Factors
High cash burn and negative free cash flow
Sustained, large negative operating and free cash flows indicate the company cannot self-fund development or commercialization. Over the medium term this raises persistent financing needs, increases dilution risk, and constrains strategic flexibility if clinical timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory milestone - BLA acceptance
BLA acceptance is a durable de-risking step that moves ozekibart from trial-stage toward commercialization. If approved, it would be the company's first product and the first systemic therapy for this rare cancer, creating a unique market position and potential sustained revenue stream.
Read all positive factors
Inhibrx Biosciences Inc (INBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.20B
Dividend YieldN/A
Average Volume (3M)317.27K
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue Growth550.00%
EPS Growth-107.04%
CountryUS
Employees110
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.39
Shares Outstanding14,671,186
10 Day Avg. Volume232,714
30 Day Avg. Volume317,272
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)153.07
Price to Sales (P/S)941.13
P/FCF Ratio-9.42
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue943.29
Enterprise Value/Gross Profit-2.65K
Enterprise Value/Ebitda-10.56
Forecast
1Y Price Target
$277.50Price Target Upside240.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-9.24
Revenue Forecast (FY)N/A
Inhibrx Biosciences Inc Business Overview & Revenue Model
Company Description
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic ca...
How the Company Makes Money
Inhibrx Biosciences, Inc. is a clinical-stage biotechnology company and does not have a stable, product-based commercial revenue stream typical of mature pharmaceutical companies. The company’s cash inflows generally come from (1) collaboration an...
Inhibrx Biosciences Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
25
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.30M | 1.30M | 200.00K | 1.80M | 2.19M | 7.13M |
| Gross Profit | -463.00K | -1.18M | -2.08M | 609.00K | -107.99M | 4.44M |
| EBITDA | -116.10M | -125.37M | 1.70B | -206.69M | -125.82M | -75.37M |
| Net Income | -130.19M | -140.06M | 1.69B | -241.36M | -145.23M | -81.77M |
Balance Sheet | ||||||
| Total Assets | 183.97M | 146.48M | 180.77M | 307.89M | 290.88M | 150.45M |
| Cash, Cash Equivalents and Short-Term Investments | 161.66M | 124.22M | 152.60M | 277.92M | 273.87M | 131.30M |
| Total Debt | 5.90M | 107.01M | 8.05M | 210.14M | 207.10M | 72.14M |
| Total Liabilities | 205.00M | 138.49M | 47.18M | 264.39M | 232.82M | 98.07M |
| Stockholders Equity | -21.04M | 7.99M | 133.58M | 43.50M | 58.06M | 52.38M |
Cash Flow | ||||||
| Free Cash Flow | -131.94M | -129.82M | -197.01M | -197.90M | -115.99M | -81.19M |
| Operating Cash Flow | -131.93M | -129.79M | -194.41M | -193.31M | -115.30M | -80.32M |
| Investing Cash Flow | -7.00K | -28.00K | -2.60M | -4.59M | -686.00K | -809.00K |
| Financing Cash Flow | 77.07M | 101.45M | 71.68M | 201.96M | 258.55M | 83.77M |
Inhibrx Biosciences Inc Technical Analysis
Negative
81.55
Price Trends
91.86
Negative
92.80
Negative
84.51
Negative
Market Momentum
-3.30
Negative
43.37
Neutral
62.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBX, the sentiment is Negative. The current price of 81.55 is below the 20-day moving average (MA) of 86.62, below the 50-day MA of 91.86, and below the 200-day MA of 84.51, indicating a bearish trend. The MACD of -3.30 indicates Negative momentum. The RSI at 43.37 is Neutral, neither overbought nor oversold. The STOCH value of 62.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INBX.
Inhibrx Biosciences Inc Risk Analysis
Inhibrx Biosciences Inc disclosed 88 risk factors in its most recent earnings report. Inhibrx Biosciences Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inhibrx Biosciences Inc Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.50B | -8.83 | -28.77% | ― | -23.48% | 25.73% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | $1.74B | -11.90 | -14.86% | ― | 242.66% | 15.53% | |
53 Neutral | $1.61B | -16.02 | -37.79% | ― | -12.98% | 8.99% | |
50 Neutral | $1.20B | -9.78 | -563.89% | ― | 550.00% | -107.04% | |
48 Neutral | $1.72B | -90.30 | -4.83% | ― | 23.64% | ― | |
44 Neutral | $1.16B | -4.39 | -45.27% | ― | -72.09% | -754.83% |
* General Sector Average
INBX
Inhibrx Biosciences Inc
83.89
62.91
299.86%
XNCR
Xencor
19.84
12.35
164.89%
ZYME
Zymeworks
23.50
11.09
89.36%
IMTX
Immatics
9.77
3.43
54.10%
ABCL
AbCellera Biologics
5.92
1.80
43.69%
IMCR
Immunocore Holdings
33.29
1.19
3.71%
Inhibrx Biosciences Inc Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Inhibrx Biosciences Expands Credit Facility to $500 Million
Positive
Jul 17, 2026
On July 15, 2026, Inhibrx Biosciences Inc. amended its Loan and Security Agreement with Oxford Finance, expanding its credit facility to as much as $500 million and adding a new $325 million tranche. The company received an immediate $100 million ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy
Positive
Jun 15, 2026
On June 15, 2026, Inhibrx Biosciences Inc. announced that the U.S. Food and Drug Administration accepted for filing its Biologics License Application for ozekibart (INBRX-109) to treat patients with unresectable or metastatic conventional chondros...
Executive/Board ChangesShareholder Meetings
Inhibrx Biosciences Holds 2026 Virtual Annual Shareholder Meeting
Neutral
Jun 3, 2026
Inhibrx Biosciences Inc. held its 2026 Annual Meeting of Stockholders on June 3, 2026, in a virtual format, with approximately 79% of the 14.6 million eligible common shares present or represented by proxy, underscoring strong shareholder particip...
Business Operations and StrategyProduct-Related Announcements
Inhibrx Biosciences Reports Positive Interim Phase 2 Results
Positive
May 11, 2026
On May 11, 2026, Inhibrx Biosciences reported positive interim Phase 2 data from its HexAgon trial evaluating INBRX-106, a hexavalent OX40 agonist, plus pembrolizumab versus pembrolizumab alone in first-line, PD-L1 high metastatic or unresectable ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.